Why did AFME.PA stock jump in pre-market trade?

The pre-market jump to **€3.70** looks driven by momentum and technical breakout rather than confirmed corporate news. High relative activity and overbought indicators suggest trader-led buying. Confirm any catalysts before trading.

What are the main risks for AFME.PA investment?

Primary risks are negative earnings (**EPS -€0.36**), tight liquidity, high valuation vs revenue (P/S **23.52**), and potential clinical or regulatory setbacks common in medical devices. Position sizing is crucial.

How should traders manage AFME.PA stock volatility on EURONEXT?

Use limit orders, smaller lot sizes, and predefined stop losses. Expect wide spreads and fast moves; consider scaling in and monitor RSI (**92.84**) and volume for exhaustion signals.

What does Meyka AI forecast for AFME.PA?

Meyka AI's forecast model projects a monthly figure near **€3.60** and a yearly figure **€1.71**, implying downside versus current price. Forecasts are model-based projections and not guarantees.

EU Stocks

AFME.PA Affluent Medical (EURONEXT) +31.67% to €3.70 Feb 23, 2026: volume surge

ByHuzaifa Zahoor February 23, 2026February 23, 2026

We see AFME.PA stock gap higher in pre-market trade after a strong intraday run, rising 31.67% to €3.70 on EURONEXT on Feb 23, 2026. Volume is elevated at 27,635 shares versus an average of 27,900, flagging active buying in this small-cap healthcare device maker. The move occurred alongside a breakout above the 50-day average (€1.78) and heavy technical overbought readings. Traders should weigh rapid upside against weak profitability metrics, while buyers watch for follow-through or a quick pullback.